Indonesia's government said 1.2 million doses of a COVID-19 vaccine developed by China-based biopharmaceutical company Sinovac Biotech arrived in the country late Sunday.
President Joko Widodo said in a televised address that another 1.8 million doses of the vaccine are expected to arrive in early January.
We are very grateful, thank God, the vaccine is now available so that we can immediately curb the spread of the COVID-19 disease, Widodo said.
The government is still waiting for millions of other doses of the Sinovac vaccine to arrive in the form of raw materials that will be further processed by state-owned pharmaceutical holding company PT Bio Farma.
However, Widodo said that emergency use authorization from the country's Food and Drug Control Agency is still needed for mass vaccinations to start.
Indonesia is already cooperating with Sinovac in phase 3 clinical trials of its vaccine candidate, with tests being carried out on 1,620 volunteers in West Java's Bandung city since August. The government also looked into partnerships with two other Chinese drug manufacturers, Sinopharm and CanSino Biologics.
Penny Lukito, head of the Food and Drug Control Agency, estimated that the Sinovac vaccine would obtain emergency use authorization from the agency by the third or fourth week of January, after the agency evaluates interim results from the third-stage clinical trial.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU